The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)

Gerd Brunner, Eric Y. Yang, Anirudh Kumar, Wensheng Sun, Salim S. Virani, Smita I. Negi, Tyler Murray, Peter H. Lin, Ron C. Hoogeveen, Changyi Chen, Jing Fei Dong, Panagiotis Kougias, Addison Taylor, Alan B. Lumsden, Vijay Nambi, Christie M. Ballantyne, Joel D. Morrisett

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Methods: A total of 102 patients were randomized to either mono-therapy with simvastatin (40mg daily) or triple-therapy with simvastatin (40mg daily), extended-release niacin (1500mg daily), and ezetimibe (10mg daily). MRI was performed at baseline and 6, 12, and 24 months. SFA wall, lumen, and total vessel volumes were quantified. MRI-derived SFA parameters and lipids were analyzed with multilevel models and nonparametric tests, respectively. Results: Baseline characteristics did not differ between mono and triple-therapy groups, except for ethnicity ( p=0.02). SFA wall, lumen, and total vessel volumes increased non-significantly for both groups between baseline and 24-months. Non-high-density lipoprotein cholesterol was significantly reduced at 12 months with triple-therapy compared with mono-therapy ( p=0.01). Conclusion: No significant differences were observed between mono-therapy using simvastatin and triple-therapy with simvastatin, extended-release niacin, and ezetimibe for 24-month changes in SFA wall, lumen, and total vessel volumes. Clinical Trial Registration Information: NCT00687076; Link: http://clinicaltrials.gov/ct2/show/. NCT00687076.

Original languageEnglish (US)
Pages (from-to)371-377
Number of pages7
JournalAtherosclerosis
Volume231
Issue number2
DOIs
StatePublished - Dec 2013

Keywords

  • ABI
  • Atherosclerosis
  • ICC
  • Lipids
  • Magnetic resonance imaging
  • MRI
  • PAD
  • PDW
  • Peripheral artery disease
  • SFA
  • T1W
  • T2W

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)'. Together they form a unique fingerprint.

Cite this